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Abstract
Background: Targeting antigens encoded by DNA vaccines to dendritic cells (DCs) in the presence of adjuvants enhances
their immunogenicity and efficacy in mice.
Methodology/Principal Findings: To explore the immunogenicity of this approach in non-human primates, we generated a
single chain antibody to the antigen uptake receptor DEC-205 expressed on rhesus macaque DCs. DNA vaccines encoding
this single chain antibody fused to the SIV capsid protein were delivered to six monkeys each by either intramuscular
electroporation or conventional intramuscular injection co-injected or not with poly ICLC, a stabilized poly I: C analogue, as
adjuvant. Antibodies to capsid were induced by the DC-targeting and non-targeting control DNA delivered by
electroporation while conventional DNA immunization at a 10-fold higher dose of DNA failed to induce detectable humoral
immune responses. Substantial cellular immune responses were also observed after DNA electroporation of both DNAs, but
stronger responses were induced by the non-targeting vaccine. Conventional immunization with the DC-targeting DNA at a
10-fold higher dose did not give rise to substantial cellular immune responses, neither when co-injected with poly ICLC.
Conclusions/Significance: The study confirms the potent immunogenicity of DNA vaccines delivered by electroporation.
Targeting the DNA via a single chain antibody to DEC-205 expressed by DCs, however, does not improve the
immunogenicity of the antigens in non-human primates.
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Introduction
DNA immunization is a promising vaccine platform with
potential applications in prevention and treatment of infectious
diseases and cancer. A number of different strategies are currently
explored in more than 40 clinical trials to improve DNA
vaccination (reviewed in [1]). One approach to improve the
immunogenicity and efficacy of DNA vaccines is the targeting of
the encoded antigen to molecules expressed by dendritic cells
(DCs) such as DEC-205 (CD205) (Fig. 1). Notably, co-injection of
DEC-205-targeted protein antigens with poly I: C or its analogue,
poly ICLC that is stabilized against serum nucleases, which both
bind to the innate pattern recognition receptors, Toll-like receptor
3 (TLR3) and melanoma differentiation-associated gene-5 (MDA-
5) [2,3], leads to increased antigen-specific T cell and B cell
responses in mice [4–6] and non-human primates [7–9]. Injection
of DC-targeted antigens in the absence of adjuvants, however,
induces initial T cell proliferation, but this is not followed by strong
CD4
+ and CD8
+ effector T-cell responses due to peripheral
deletion, tolerance and/or induction of regulatory T cells [10–16].
Consistent with the results observed with the injection of DC-
targeted proteins without adjuvants, we have also observed
reduced immune responses after conventional intramuscular
immunization with DNA encoding DC-targeted antigens in
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contrast, in the presence of TLR ligands, the immunogenicity of
DC-targeting DNA vaccines was higher than that of the non-
targeting control. Similarly, delivery of a DNA vaccine encoding
DEC-205-targeted HIV Gag to mice by electroporation enhanced
the efficacy of DNA vaccination in the absence of additional
adjuvants [18]. In this situation, the strong inflammatory response
known to be induced by intramuscular electroporation [19] might
have overcome the requirement for other co-stimulatory signals.
The potent enhancement of antigen uptake by DCs and the
ease of production of DNA vaccines would allow rapid testing of
the immunogenicity of DEC-205-targeting DNA vaccines in
humans. However, we felt that prior to advancing this approach
into clinical trials, the immunogenicity of such immunization
protocols should be evaluated in non-human primates. We
therefore constructed and characterized a single chain antibody
to the DEC-205 receptor of rhesus macaques and explored the
immunogenicity of DNA vaccines encoding a fusion protein
between the single chain antibody and the SIV p27 capsid antigen
in this primate species. To evaluate the effect of DC-targeting, the
targeting vaccine and a non-targeting control DNA were delivered
by intramuscular electroporation and the SIV-specific cellular and
humoral immune responses were compared. Additionally, we
determined the impact of the application of poly ICLC as adjuvant
on the immunogenicity of DC-targeting during conventional DNA
immunization.
Results
Construction and characterization of single chain
antibody to DEC-205 of rhesus macaques
To generate a single chain antibody to rhesus macaque DEC-
205, we first explored whether 3G9, a monoclonal antibody (mAb)
generated by immunization of human immunoglobulin transgenic
mice with human DEC-205 [5], cross-reacts with the macaque
protein. Lymph node sections from macaques not previously
exposed to HIV or SIV antigen were incubated with 3G9 coupled
to the HIV-p41 Gag fragment (3G9-p41). This mAb consists of
human IgG1 constant domains and a truncated HIV p55 protein,
and subsequent incubation with antibodies against these antigens
revealed binding of 3G9-p41 to large cells with abundant
cytoplasm, which were located in the T-cell region as indicated
by the presence of high endothelial venules (Fig. 2 A and B). No
immunolabeling was seen when anti-p24 (Fig. 2C) or 3G9-p41
(data not shown) was omitted (Fig. 2C). Thus, 3G9 coupled to the
HIV-p41 Gag fragment recognizes antigens, most likely expressed
by myeloid DCs, in monkey lymphoid tissue.
To further explore possible in vivo targeting, 3G9-p41 was
injected s.c. in the groin of three rhesus macaques. After 48 hours,
a lymph node draining the injection site as well as a contralateral
Figure 1. Principle of targeting of antigens encoded by DNA
vaccines to DCs. The coding region of variable heavy (VH) and light
(VL) chains of antibodies to uptake receptors of DCs are fused in frame
to the open reading frame of the antigen. After delivery of the DNA
vaccine, transduced cells of the immunized individual produce and
secret a single chain antibody to the uptake receptor coupled to the
antigen. Binding of the single chain to the uptake receptors should
increase uptake and presentation of the antigen by the DCs.
doi:10.1371/journal.pone.0039038.g001
Figure 2. In vitro and in vivo binding of anti-DEC-205-p41 to
DCs located in rhesus macaque lymph nodes. (A–C) Frozen
sections from control lymph nodes were incubated with 3G9-p41
followed by anti-IgG (brown in A) or anti-HIV capsid mAb (red in B)
staining. No immunolabeling was seen when anti-HIV capsid mAb was
omitted (C). (D–H) 48 h after s.c. application of 3G9-p41, draining (D; E,
marginal sinus) and contralateral (F) lymph nodes were removed and
sections were stained with anti-HIV capsid antibody (red). The high
endothelial venules as characteristic structures of the T-cell area of the
lymph node are highlighted by arrows. Targeting of DCs by 3G9-p41
was verified by double labeling of the sections with CD1a (red in G, blue
in H), which is expressed by immature DCs, or CD83 (red in I), typically
expressed by mature DCs, and anti-p24 (green in G and I, red in H).
doi:10.1371/journal.pone.0039038.g002
DC-Targeted DNA Vaccines in Rhesus Monkey
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by using an anti-HIVp41 mAb, labeled cells were found scattered
in both lymph nodes (Fig. 2D and F) as well as in the marginal
sinus of the draining node indicating migrating cells, which is
typical for DCs (Fig. 2E). Comparable results were found for all
three monkeys. The findings suggest systemic distribution of the
injected 3G9-p41 by the targeted cells. As observed before in vitro,
the target cells were mainly localized in the T-cell zone as
indicated by the presence of high endothelial venules. This finding
and the cellular morphology of the labeled cells strongly suggested
that interdigitating myeloid DCs were targeted by the antibody.
To determine the lineage of the immunostained cells, we
performed double staining with mAbs recognizing molecules
typically expressed by immature (CD1a) or mature DCs (CD83).
Immunofluorescence and immunohistochemistry revealed co-
localization of 3G9-p41 with both CD1a
+ and CD83
+ cells
(Fig. 2G–I).
To construct a single chain antibody with the binding specificity
of 3G9, we cloned the reading frames of the variable heavy and
light chain of 3G9 in frame to the coding region of SIV p27 capsid
and tagged with the OLLAS epitope [20] (scDEC-p27). As a
control, a single chain antibody to an irrelevant antigen was fused
to SIV p27-OLLAS (scISO-p27). Since one critical step for our
vaccination is the comparable expression and secretion of our
fusion proteins from transduced muscle cells, we transfected 293 T
cells with graded doses of the expression plasmids to ensure
comparable expression levels over a broad concentration range. In
the supernatant of the transfected cells, the secreted fusion proteins
of the expected size were detected in comparable amounts for both
plasmids by Western Blot analysis (Fig. 3A). To confirm specific
binding to DEC-205, immature and mature rhesus macaque DCs
were generated from peripheral blood monocytes, incubated with
the supernatants of 293T cells transfected with scDEC-p27 or
scISO-p27, and subsequently stained with a mAb to OLLAS. We
observed binding of scDEC-p27, but not of scISO-p27, to mature
and to a lesser extent to immature DCs (Fig. 3 B), which express
less DEC-205 than mature DCs [21]. This mirrored binding
experiments on human DCs and CHO cells stably expressing
huDEC205 and confirmed the cross-reactivity of the single-chain
antibody (data not shown).
Immunogenicity of DNA encoding DEC-205-targeted
antigen
To directly evaluate the effect of targeting antigens encoded by
DNA vaccines to DEC-205 on the immunogenicity, one group of
six rhesus monkeys (group A) was immunized with scDEC-p27
while group B received scISO-p27. Both groups were immunized
twice (week 0 and 8) at a dose of 0.1 mg DNA by intramuscular
electroporation. Two additional groups (group C and D) received
1 mg of scDEC-p27 twice by conventional intramuscular injec-
tion. In group C, the DNA vaccine was co-injected with poly
ICLC as adjuvant.
Two, five and eight weeks after the second immunization,
PBMCs were stimulated with aldrithiol-2-inactivated SIV (AT2-
SIV) (Fig. 4 A) or a pool of selected peptides spanning the SIVgag
polyprotein (Gag-peptide) (Fig. 4 B) to determine the T-cell
response in an IFN-c ELISPOT assay. Two weeks after the second
immunization, both groups vaccinated by electroporation showed
consistently moderate to high numbers of IFN-c secreting cells
which then gradually decline over time. The mean responses were
significantly higher in the group primed with the non-targeting
DNA (group B) compared to those observed in group A (Gag-
peptide stimulated cultures at week 16, AT2-SIV stimulated
cultures at weeks 10 and 13; p,0.05 by One-way ANOVA).
Although groups C and D had received a 10-fold higher dose of
DNA than groups A and B, IFN-c producing cells were only
detectable occasionally after conventional DNA immunization
with scDEC-p27 (Fig. 4).
We determined SIV-specific proliferative responses in CFSE-
dilution assays. Strongest responses were seen in the animals from
group B where proliferation of CD4
+ and CD8
+ T cells was
detected as early as week 8 and furthermore at weeks 10 and 13
after immunization (Fig. 5). Two immunizations were needed for
the animals of group A to develop proliferative CD4
+ and CD8
+
T-cell responses, which already declined at week 13. In contrast,
T-cell proliferative responses by the animals of groups C or D
never exceeded significantly the values obtained at baseline (Fig. 5).
We further characterized the T-cell responses by determining
the concentrations of IFN-c, IL-4, IL-10, and IL-17 in superna-
tants collected from re-stimulated PBMCs 48 h after setting up the
assays. Cells from animals of group A produced significantly more
Figure 3. Expression and characterization of the antigen and verification of binding to rhesus macaque DCs. 293 T cells were
transiently transfected with grading doses (from 3 to 0,003 mg) of scISO-p27 or scDEC-p27 expressing plasmids (pV-scISO-p27 or pV-scDEC-p27).
Additionally, 293 T cells were transfected with 3 mg of a GFP-expressing plasmid as negative control. Supernatants were harvested 48 h after
transfection and secreted fusion proteins were detected by Western Blot analysis to confirm comparable expression levels (A). Monocyte-derived
rhesus macaque DCs were incubated with supernatants of transfected 293 T cells, and bound fusion proteins were visualized by using an Alexa647-
labeled a-OLLAS antibody. Subsequent FACS-analyses are shown for scDEC-p27 (filled grey histogram) and scISO-p27 (open black histogram) for
immature and mature DCs (B).
doi:10.1371/journal.pone.0039038.g003
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from group B monkeys at weeks 10 and 13 (Fig. 6). Consistent with
the results of the IFN-c ELISPOT and the CFSE dilution assays,
we also detected significantly more IFN-c in supernatants from
cells derived from group B than from group A animals (Fig. 6). In
contrast, we did not detect substantial amounts of IFN-c in
supernatants from cells derived from the animals of groups C or D.
Notably we were unable to detect considerable amounts of IL-4,
IL-10, or IL-17 in the supernatants from assays set up with
PBMCs from either group of animals (data not shown).
Similar observations were made using tetramer staining for the
detection of SIV-specific CD8
+ T cells. Since three animals of each
group were Mamu-A*01 positive, we were able to identify CD8
+ T
cells specific for the immunodominant SIVgag CM9 epitope.
Although the overall responses were rather low in the immunized
animals, tetramer positive cells were mainly detectable in the
blood of monkeys, which had received the DNA followed by
electroporation (Fig. 7). Again, the non-targeting DNA tended to
induce higher responses than DC-targeting DNA.
The humoral immune response after vaccination was monitored
by measuring Gag-specific antibodies. After two immunizations
with DNA vaccines encoding either DEC-205 targeted or non-
targeted antigen by electroporation, Gag antibodies were readily
detectable in all animals of group A and B (Fig. 8), with
approximately 2-fold higher antibody titers in group B. In
contrast, conventional immunization with DNA encoding DEC-
205 targeted antigens did not induce detectable levels of Gag
antibodies even when poly ICLC had been used as adjuvant.
Discussion
Our study aimed at improving the immunogenicity of DNA
vaccines in primates by targeting the encoded antigen to an
antigen-uptake receptor expressed by myeloid DCs, DEC-205
[22]. Since earlier mouse studies demonstrated the need for the
simultaneous delivery of an adjuvant to generate robust T-cell
responses after DC-targeted vaccination [4,11,12,17], we either
delivered the DNA by electroporation or injected it together with
the TLR3-ligand poly ICLC that has previously been shown to
augment protein-specific cellular immune responses in non-human
primates [7,8]. One of the most impressive improvements by DC-
targeting DNA vaccines in mice were the high immunogenicity at
rather low doses [18], which was the reason that suboptimal doses
of DNA were used for the intramuscular injection and the
electroporation approach. The failure of DC-targeting DNA,
independent of the use of poly ICLC, to induce substantial
immune responses after intramuscular injection might therefore be
a consequence of low antigen expression levels in vivo. The low
immunogenicity of this ‘‘classical’’ injection protocol is in line with
previous reports on DNA vaccines, which resulted in poor CTL or
antibody responses after two immunizations with comparable or
even higher amounts of gag and env-expressing plasmids [23,24].
The addition of poly ICLC could not enhance the immunogenicity
of our DNA vaccine, although the immunization with DC-
targeted protein plus poly ICLC as adjuvant has proven to be a
successful strategy [4–8]. This might be a consequence of the
delayed antigen expression after DNA delivery compared to
protein vaccines, where poly ICLC and the targeted antigen are
available at the same time. For DNA vaccines encoding DEC-
targeted protein, it may be possible that the inflammatory response
induced by poly ICLC within hours (i.e., maximum CXCL10
Figure 4. Induction of SIV-specific IFN-c secreting cells by control but not by DEC-205 targeting DNA. At weeks 10, 13, and 16, PBMCs
were stimulated for 17–20 h with either AT2-inactivated SIV (A) or a Gag-specific peptide pool (B), and numbers of IFN-c producing cells were
determined in ELISPOT assays. Numbers of spots per 10
6 cells are presented for each animal and each point in time (line, median; #,p ,0.05
compared with C and D, {,p ,0.05 compared with A; one-way ANOVA followed by Bonferroni Post test).
doi:10.1371/journal.pone.0039038.g004
DC-Targeted DNA Vaccines in Rhesus Monkey
PLoS ONE | www.plosone.org 4 June 2012 | Volume 7 | Issue 6 | e39038serum levels are detectable 18 h after s.c. injection [9], have
already declined before appreciable levels of antigens are
expressed. Thus, for a prolonged period of time following
immunization, antigen would be produced in vivo in the absence
of adjuvant. Subsequent strategies may therefore focus on other
adjuvants, e.g., DC-activating cytokines, such as GM-CSF or Flt-3
ligand, that could be included in the DNA constructs and thereby
would be present for the entire period of antigen expression. Co-
expression of GM-CSF during DNA immunization has been
shown to enhance cellular as well as humoral immune responses in
monkeys [25,26]. Furthermore, expression of Flt-3 ligand
expanded DC-populations in monkeys and was shown to act
together with a TLR-9 ligand as potent adjuvant for DNA vaccine
resulting in strong cellular immunity to SIV [27].
In comparison to the conventional intramuscular injection, the
delivery of DNA by electroporation proved to considerably
enhance the immunogenicity of the injected DNA. This is in line
with previous reports where the immunogenicity of DNA vaccines
against a variety of infectious agents, e.g. HIV/SIV, HCV, or
Bacillus anthracis, could be improved by applying electric pulses
together with the DNA [28–32]. In our study, the non-targeting
DNA elicited humoral and cellular responses, which were
comparable to previous studies using DNA electroporation with
comparable doses (100 mg–250 mg) [29,33]. Although it is difficult
to compare different vaccine studies due to differences in the
antigens, dosages and application routes applied, our administra-
tion protocol seems to be well suited to generate antigen-specific
immune responses in the non-human primate model. The
response seems to be dominated by CD4 T cell responses and is
in line with the study of Rosati et al, in which the immune
response against the native form of Gag was also predominantly
composed of CD4 cells [29]. However, targeting the antigen to
DCs in rhesus macaques did not enhance the humoral immune
response and reduced the cellular immune response. This is in
sharp contrast to the observations in the mouse model [18]. Since
our targeted and non-targeted antigens only differ in the specificity
of the single chain antibody and showed comparable expression
and secretion efficiencies, the reduced immunogenicity is most
likely due to the targeting of DCs. Although we could not analyze
Figure 5. Development of proliferative CD4
+ and CD8
+ T-cell
responses following DNA immunization. Before and at the
indicated time points following immunization, CFSE-labeled PBMCs
were incubated with AT-2 SIV or microvesicles. On day 7, T-cell
proliferation was assessed as the percentage of CFSE
low CD4
+ (gating
on live CD3
+CD8
2, A) and CD8
+ (gating on live CD3
+CD8
+, B) T cells.
Data obtained with microvesicles were subtracted, and means and
standard error of the means (SEM) are shown (#,p ,0.05 compared
with C and D, {,p ,0.05 compared with A; one-way ANOVA followed by
Bonferroni Post test; *, p,0.05 for differences to baseline; two-way
ANOVA).
doi:10.1371/journal.pone.0039038.g005
Figure 6. Analysis of cytokine secretion by PBMCs following
SIV-restimulation. At the indicated time points, PBMC were
incubated with AT2-inactivated SIV, microvesicles, or SEB as control.
Culture supernatants were harvested after 48 h and concentrations of
IFN-c were determined by ELISA. Data obtained with microvesicles were
subtracted, and means and SEM are shown (#,p ,0.05 compared with
C and D, {,p ,0.05 compared with A; one-way ANOVA followed by
Bonferroni Post test; *, p,0.05 for differences to baseline; two-way
ANOVA). Substantial concentrations of IL-4, IL-10, or IL-17 were not
detected in supernatants of SIV-stimulated cells derived from either
group (data not shown).
doi:10.1371/journal.pone.0039038.g006
Figure 7. Tetramer analysis of antigen-specific CD8
+ T-cell
responses. Antigen-specific CD8
+ T-cells were analyzed by tetramer
staining for the immunodominant CM9 epitope at week 13. Lympho-
cytes from PBMC were stained for CD45, CD3, and CD8. The mean
percentages of CM9-tetramer positive cells in CD8 T
+ cells are shown for
individual animals in each group (p,0.05 compared with C and D, {,
p,0.05 compared with A; one-way ANOVA followed by Bonferroni Post
test).
doi:10.1371/journal.pone.0039038.g007
DC-Targeted DNA Vaccines in Rhesus Monkey
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clearly demonstrate binding of the scAb to rhesus DCs comparable
to human DCs. It has been previously shown that coupling of
antigen to either DEC205-specific antibodies or scAb lead to
efficient antigen uptake and presentation by human DCs [34,35].
Therefore we hypothesize that differences in the antigen
presentation by DCs after DEC-targeting and non-targeting
DNA immunization are the underlying reason for the reduced
immunogenicity we observed in rhesus macaques. Since immuni-
zation with DEC-205-targeted antigens in the absence of DCs
maturation stimuli has been shown to induce tolerance rather than
immunity in mice [10,11,15,16], it is a plausible hypothesis that
comparable processes were induced in non-human primates as
well. Therefore, the induction of regulatory T-cells or depletion of
antigen-specific T-cells could be potential consequences of DC-
targeting in the absence of a strong adjuvant resulting in reduced
immune response or tolerance. While there is no direct evidence
for this in non-human primates so far, one could test this
hypothesis by injecting a related protein antigen after immunizing
monkeys with DC-targeting DNA. If tolerance had been induced
by the DNA injection, one would expect considerably lower (if
any) immune responses in pre-injected animals, and subsequent
experiments should address this important issue.
In conclusion, although we did not observe enhanced antigen-
specific immune responses by targeting the antigen encoded by a
DNA vaccine to DEC-205 in nonhuman primates, targeting of
protein vaccines to DCs remains an attractive vaccine strategy.
However, a better understanding of the in vivo requirements for
DC-driven T-cell activation in primates and humans is needed to
explore the full potential of DC-targeted vaccines and to turn the
enhanced antigen presentation into potent and protective immune
responses. Co-delivery of DNA encoding stimulatory molecules
might be a promising avenue for further investigation of DC-
targeting DNA vaccines.
Materials and Methods
Animals
To initially prove binding of the complete anti-DEC205
antibody in non-human primates three young adult colony-bred
male rhesus macaques (Macaca mulatta) from China were used. For
the DNA immunization study twenty-four young adult colony-
bred Indian-origin rhesus macaques of either sex were assigned to
four experimental groups with six animals each. All animals were
housed at the German Primate Center under conditions according
to the German Animal Welfare act complying with the European
Union guidelines on the use of non-human primates for
biomedical research. This includes measures of animal welfare
and amelioration of suffering in all work such as a 12:12 light dark
schedule, provision of monkey biscuits supplemented with fresh
fruit twice a day and constant water access. Additionally, the
monkeys were kept under permanent medical supervision. In cases
of suffering predefined by a scoring system on termination criteria,
monkeys were humanely killed. Both, the DEC205-binding study
as well as the DNA immunization study were approved by an
external ethics committee authorized by the Lower Saxony State
Office for Consumer Protection and Food Safety and performed
with the project licenses 33.9.42502-04-072-08 and 33.9.42502-
04-017/07, respectively, issued by the same State Office. All
animals were seronegative for SIV, simian retrovirus, and T-cell
leukemia virus. Major histocompatibility complex (MHC) class I
allele genotyping of the macaques of Indian origin was carried out
as described before [36,37]. 12 macaques were identified carrying
the Mamu-A*01 allele and three each were allocated to each study
arm. For collection of blood samples animals were sedated i.m.
with 10 mg ketamine per kg body weight. For deeper anesthesia
required for immunization or lymph node removal a mixture of
ketamine, xylazine and atropine was used.
Construction and characterization of DNA vaccines
The fusion of the single chain antibodies scDEC and ISO to
HIV antigen was previously described [17,18]. A codon-optimized
plasmid encoding the control antibody fused to SIVgag (pV-
scISO-gag) was obtained from Geneart. To generate p27-OLLAS
containing fusion proteins, the sequence was amplified by PCR
including the OLLAS sequence [20] in the antisense primer of
p27. The PCR product was cloned in place of full-length SIVgag
resulting in pV-scISO-p27. Furthermore, the sequence of the
scDEC single chain based on the monoclonal antibody 3G9 [5]
was amplified by PCR and replaced the sequence of the control
antibody. The resulting plasmid was referred to pV-scDEC-p27.
Both plasmids were based on the pVAX backbone plasmid
(Invitrogen) where the antigen expression is driven by a CMV
promoter. For in vivo studies, plasmids were purified with the
NucleoBondH PC 10.000 EF Kit (Macherey-Nagel, Du ¨ren,
Germany) according to the manufacturer’s protocol and then
tested for endotoxin levels with the LAL quantification assay
(Cambrex Bio Science, Verviers, Belgium) confirming that the
dose used for immunization contained less than 0.1 EU
(Endotoxin Units).
To verify equal expression levels of the two plasmids, 293 T cells
were transiently transfected in the presence of polyethlyeneimine
(PEI) as described elsewhere [38] and supernatants were harvested
after 48 h and subjected to western blot analysis. The secreted
fusion proteins were detected by the combination of a-OLLAS
[20] and rabbit-a-ratIg-HRP antibodies (Dako). Moreover,
supernatants were tested for their binding capacity to DEC-205
expressed by rhesus macaque DCs. Monocyte-derived immature
and cytokine-activated, mature DCs were generated as previously
described [39] and incubated with supernatants of scDEC-p27 or
scISO-p27 transfected cells for 30 min at 4u. Bound fusion
proteins were stained by an Alexa647-labeled a-OLLAS antibody
and the cells were analyzed by flow cytometry on a FACScaliburH
(BD Bioscience).
Figure 8. Development of humoral immune responses follow-
ing DNA immunization. At the indicated time points, Gag-specific
serum antibody titers were analyzed using an ELISA. Data are shown as
geometric mean of six animals per group (#,p ,0.05 compared with C
and D; non-parametric ANOVA (Kruskal-Wallis) followed by a Dunns
Post test).
doi:10.1371/journal.pone.0039038.g008
DC-Targeted DNA Vaccines in Rhesus Monkey
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vivo
Lymph nodes of non-treated control macaques were selected
from our files. Five mm thick sections were prepared with a
cryostate. The sections were fixed in 4% paraformaldehyde and
incubated with the fusion protein 3G9-p41 followed by incubation
with either anti-human IgG or with anti-p24 of HIV (both from
Dakocytomation Hamburg, Germany). Binding of the polyclonal
antibody was detected by incubation with StreptABComplex/
HRP (code K0391; Dako, Hamburg, Germany) using 3-amino-9-
ethylcarbazole (Sigma-Aldrich, Deisenhofen, Germany) as the
substrate. Binding of anti-p24 was visualized using the alkaline
phosphatase anti-alkaline phosphatase (APAAP) reaction with Fast
red as substrate. The sections were counterstained with haemalaun
and mounted.
To test for binding in vivo, three rhesus monkeys received
250 mg 3G9-p41 in 1.3 ml saline in the right groin. Lymph nodes
from the same and the contralateral region were surgically
removed 48 h after antigen application and partially snap frozen
in liquid nitrogen and kept at 280uC until use. Cryostat sections
were stained with anti-p24 as described above and counterstained
with haemalaun. Double labeling for lineage characterization of
3G9-p41
+ cells was performed by an overnight incubation with
either anti-CD1a for immature (NeoMarkers, Freemont, CA;
clone 010) or anti-CD83 for mature DCs (Novocastra Laborato-
ries, Newcastle-upon-Tyne, United Kingdom). Isotype matched
secondary antibodies labeled with FITC or TRIC were applied.
The images were taken with an AxioImager M1 microscope (Carl
Zeiss, Jena Germany) running an AxioVision rel.4.6.
Immunizations
The different DNA vaccines were delivered twice spaced eight
weeks apart as follows. Group A received scDEC-p27 DNA via a
‘‘needle style’’ electroporation (EP) device (TriGridTM Delivery
System, Ichor Medical Systems, San Diego, CA). A 1 ml-syringe
with 250 ml DNA solution containing 0.1 mg DNA was loaded
into the EP device and adjusted to an injection depth of 15 mm as
advised by the manufacturer. Then syringe and device were
applied in tandem into one quadriceps muscle and the DNA was
manually delivered intramuscularly by rapid bolus injection. After
10 seconds the electrical pulse was initiated using electroporation
conditions as previously described [28]. The same procedure was
performed on the other quadriceps muscle. Group B served as a
control for the DEC-205-targeting and received non-targeted
scISO-p27 DNA at the same dose and by the same approach as
described for group A. Group C was given 1 mg scDEC-p27 DNA
mixed with 2 mg of poly ICLC (Hiltonol, Oncovir, Washington,
D.C.), by the intramuscular (i.m.) route in a final volume of 1.3 ml
delivered in equal volumes into each hamstring muscle. Finally,
group D received scDEC-p27 DNA under the same conditions as
group C, but without adjuvant.
Detection of cellular immune responses
Blood samples were drawn before and at regular intervals after
immunization to measure SIV-specific cellular and humoral
immune responses. To measure SIV-specific IFN-c secreting T-
cells, an ELISPOT assay was performed as described [40]. For
antigenic stimulation SIV Gag peptides (EVA7066.1-16, NIBSC)
and aldrithiol-2 (AT-2)-inactivated SIV (ARP1018.1, NIBSC, lot
# P4002), the latter kindly provided by the National Cancer
Institute (Frederick, MD) and distributed through NIBSC, Centre
for AIDS reagents, UK, were used. As an SIV-unrelated peptide
control stimulus, a pool of six 20-mer peptides derived from the
gHCV NS3 gene was included [41]. Inactivated microvesicles
derived from SUP-T1 cells (ARP1018.2, NIBSC, lot # P3824)
served as control stimulus for AT-2 SIV.
Proliferation assays were set up with carboxyfluorescein
diacetate succinimidyl ester (CFSE, Invitrogen/Molecular Probes,
Karlsruhe, Germany)-stained PBMCs as described [9]. Briefly,
PBMCs at 1610
7 cells/ml were stained with 0.25 mM CFSE in
pre-warmed PBS for 15 min at 37uC, washed in medium,
incubated in pre-warmed medium for another 30 min, and
washed again. The cells were cultured at 1610
5 PBMCs/well in
96-well round-bottom trays (Nunc) in the presence of AT-2 SIV
(300 ng p27/ml) or unspecific microvesicles identically prepared
(ARP1018.2, concentration adjusted to protein content of AT-2
SIV). PBMCs in medium alone or stimulated with 5 ng/ml
staphylococcal enterotoxin B (SEB; Alexis Corp., Lausen, Swit-
zerland) served as controls. All conditions were set up in triplicates
and cultures were incubated at 37uC and 5% CO2. On d 7, cells
were harvested and washed in PBS/5% FCS/0.05% sodium
azide, stained with anti-CD3 PE- and anti-CD8 PerCP-conjugated
mAbs, washed, and fixed. T cell proliferation was assessed as the
percentage of CFSE
low cells, gating on live CD3
+CD8
+ or
CD3
+CD8
– cells. Likewise, stimulated and unstimulated PBMCs
were incubated for 48 h, supernatants were harvested, and frozen
at 280uC for analyses of cytokine concentrations.
Cytokine concentrations in cell culture supernatants were
measured using ELISA kits for monkey IFN-c, IL-4, and IL-10
(all U-Cytech, Utrecht, The Netherlands) and for human IL-17
known to cross-react with monkey IL-17 (eBioscience, NatuTec,
Frankfurt/Main, Germany) [9].
MHC class I tetramer staining of SIV-specific CD8
+ T cells was
carried out for the Mamu-A*01-positive macaques. 50 ml of whole
blood was incubated for 30 min with the phycoerythrin (PE)-
conjugated tetramer Mamu-A*01 Gag181–189 (CM9, Beckman
Coulter, Krefeld, Germany) and the BD Biosciences (Heidelberg,
Germany) monoclonal antibodies anti-CD3 Alexa700 (clone
SP34-2) and anti-CD8 AmCyan (clone SK1). Following surface
staining, blood samples were treated with FACS lysing solution
(BD Biosciences). Flow cytometric analysis was performed using a
BD LSRII flow cytometer (BD Biosciences) and the list-mode data
files were analyzed using FlowJo Version 8.7 (Tree Star).
Detection of humoral immune responses
To determine humoral SIV-specific responses, a standard
ELISA for the detection of antibodies against the SIV polypeptides
gp130 SU and p27 CA [42] in a limiting-dilution format was
employed. Recombinant SIVgp130 (EVA670, NIBSC) and
SIVp27 (EVA643) were kindly provided by via NIBSC, Centre
for AIDS reagents, UK.
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